Long-term follow up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and HER2-targeting systemic therapy (HER2-Tx) for HER2+ metastatic breast cancer (MBC).
Giuseppe Gullo
No relevant relationships to disclose
Annamaria De Giorgi
No relevant relationships to disclose
Cecily Quinn
No relevant relationships to disclose
Jo Ballot
No relevant relationships to disclose
Lisa Hammond
No relevant relationships to disclose
John Crown
No relevant relationships to disclose